Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

An attractive target for therapeutic intervention is constitutively activated, mutant FLT3, which is expressed in a subpopulation of patients with acute myelocyic leukemia (AML) and is generally a poor prognostic indicator in patients under the age of 65 years. PKC412 is one of several mutant FLT3 i...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Weisberg, Ellen, Roesel, Johannes, Bold, Guido, Furet, Pascal, Jiang, Jingrui, Cools, Jan, Wright, Renee D., Nelson, Erik, Barrett, Rosemary, Ray, Arghya, Moreno, Daisy, Hall-Meyers, Elizabeth, Stone, Richard, Galinsky, Ilene, Fox, Edward, Gilliland, Gary, Daley, John F., Lazo-Kallanian, Suzan, Kung, Andrew L., Griffin, James D.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2008
נושאים:
Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2597611/
https://ncbi.nlm.nih.gov/pubmed/18820131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-138065
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים